Previous Section
Review Articles
21. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
- Author
- Schiffer CA;
- Institution
- Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA. schiffer@karmanos.org
- Journal
- N Engl J Med. 2007 Jul 19;357(3):258-65.
22. Chronic myeloid leukemia--some topical issues.
- Author
- Mughal T; Cortes J; Cross NC; Donato N; Hantschel O; Jabbour E; Kantarjian H; Melo JV; Skorski T; Silver RT; Goldman JM;
- Institution
- Journal
- Leukemia. 2007 Jul;21(7):1347-52. Epub 2007 May 10.
23. Resistance to targeted therapy in chronic myelogenous leukemia.
- Author
- Hochhaus A; Erben P; Ernst T; Mueller MC;
- Institution
- III. Medizinische Klinik, Medizinische Fakultat Mannheim, University of Heidelberg, Mannheim, Germany. hochhaus@uni-hd.de
- Journal
- Semin Hematol. 2007 Jan;44(1 Suppl 1):S15-24.
- Abstract URL
- Click here to view abstract
24. Imatinib: a review of its use in chronic myeloid leukaemia.
- Author
- Moen MD; McKeage K; Plosker GL; Siddiqui MA;
- Institution
- Wolters Kluwer Health, Adis, Auckland, New Zealand.
- Journal
- Drugs. 2007;67(2):299-320.
- Abstract URL
- Click here to view abstract
25. Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.
- Author
- Atallah E; Cortes J;
- Institution
- Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
- Journal
- Curr Opin Hematol. 2007 Mar;14(2):138-44.
- Abstract URL
- Click here to view abstract
26. Pregnancies in patients with chronic myeloid leukemia in the era of imatinib.
- Author
- Koh LP; Kanagalingam D;
- Institution
- Journal
- Int J Hematol. 2006 Dec;84(5):459-62.
27. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
- Author
- Jabbour E; Cortes J; O'Brien S; Giles F; Kantarjian H;
- Institution
- Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
- Journal
- Semin Hematol. 2007 Jan;44(1 Suppl 1):S25-31.
- Abstract URL
- Click here to view abstract
28. Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007.
- Author
- Mughal T; Goldman JM;
- Institution
- Division of Hematology and Stem Cell Transplantation, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. tariq.mughal@utsouthwestern.edu
- Journal
- Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 3:S95-101.
- Abstract URL
- Click here to view abstract
29. Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date.
- Author
- Giralt S;
- Institution
- Department of Stem Cell Transplantation and Cellular Therapies University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. e-mail: sgiralt@notes.mdacc.tmc.edu
- Journal
- Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 3:S102-4.
- Abstract URL
- Click here to view abstract
30. Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
- Author
- Mughal TI; Goldman JM;
- Institution
- Division of Hematology and Stem Cell Transplantation, University of Texas Southwestern Medical School, Dallas 75390, USA. tariq.mughal@utsouthwestern.edu
- Journal
- Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S81-4.
- Abstract URL
- Click here to view abstract
